Treace Medical Concepts, Inc. (TMCI) Earnings
Treace Medical Concepts, Inc. is expected to report next earnings on November 5, 2026 (in NaN days), with a consensus EPS estimate of $-0.26. TMCI has beaten EPS estimates in 8 of its last 12 reported quarters (average surprise +9.9% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 7, 2026 | $-0.30 | $-0.24 | +19.5% | $45M | +3.1% |
| May 8, 2026 | $-0.31 | $-0.28 | +9.7% | $47M | +2.7% |
| Nov 6, 2025 | $-0.28 | $-0.26 | +7.1% | $50M | -18.7% |
| Aug 7, 2025 | $-0.29 | $-0.28 | +3.4% | $47M | -4.9% |
| May 8, 2025 | $-0.31 | $-0.25 | +19.4% | $53M | +6.2% |
| Feb 27, 2025 | $-0.04 | $-0.01 | +75.0% | $69M | +2.3% |
| Feb 27, 2024 | $-0.09 | $-0.10 | -11.1% | $62M | +2.7% |
| Nov 9, 2023 | $-0.26 | $-0.28 | -7.7% | $41M | -30.8% |
| Mar 7, 2023 | $-0.13 | $-0.08 | +38.5% | $50M | +11.2% |
| May 5, 2022 | $-0.20 | $-0.16 | +20.0% | $29M | +11.6% |
| Mar 3, 2022 | $-0.01 | $-0.12 | -2300.0% | $33M | +3.3% |
| Nov 4, 2021 | $-0.12 | $-0.12 | +0.0% | $22M | +2.9% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · August 7, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
### Core Financial & Volume Performance - Q2 2026 results saw sequentially improving revenue growth, with stronger adjusted EBITDA and reduced cash usage compared to the prior year - Year-over-year case volume growth accelerated to high single digits, driven by market share gains from adoption of the company's comprehensive bunion portfolio and new broader foot and ankle technologies ### Bunion Market Penetration Strategy - The 3 new bunion systems launched in Q3 2025 (Nanoplasty, percuplasty, Speed MTP) expand the company's addressable market to cover the 75% of existing surgeon procedure volume not previously served by core Lapaplasty - As of Q2 2026, 40% of the company's 3,300+ existing Lapaplasty surgeon customers have used at least one of the three new systems, up from 35% in Q1 2026 - Approximately 30% of new surgeons who first joined Treace via the new bunion systems have also adopted Lapaplasty, demonstrating a positive pull-through effect ### Core Lapaplasty Franchise Advancement - The next-generation Lapaplasty Lightning platform remains on track for a limited commercial launch in Q4 2026, featuring new 3D correction instrumentation and speed TMT implants to improve workflow, accuracy, and procedure time - The company is prioritizing adoption of Intelliguide, its proprietary patient-specific planning and cut guide system, which simplifies complex deformity and revisional surgeries for surgeons ### Adjacent Foot & Ankle Portfolio Expansion - A limited commercial release of the SuperBite compression screw system occurred in Q2 2026, with positive early feedback and customer uptake; full commercial launch is planned for Q3 2026 - SuperBite enables the company to enter a broad range of incremental foot and ankle procedures, often driving additional use of other Treace products - Initial clinical cases have been completed for the HyperPlate XM dynamic compression locking implant system for midfoot and hindfoot fusions, alongside the recently commercialized Great Release XM soft tissue instrument - The single-use Cartoblaster powered joint preparation rasp is planned for launch in Q4 2026 to complete the mid/hindfoot fusion portfolio, expanding the company's U.S. total addressable market by approximately $300 million
Guidance
- Full year 2026 revenue guidance was raised to a range of $204 million to $212 million, up from the prior guidance range of $202 million to $212 million; this range represents a 4% to 0% decline compared to full year 2025 - Full year 2026 adjusted EBITDA guidance was updated to a loss of $3 million to $5 million, improved from the prior guidance of a $4 million to $6 million loss - The company reaffirmed its expectation that full year 2026 cash usage will be approximately 50% lower than full year 2025 - Management expects the company to return to positive year-over-year revenue growth in the seasonally strongest fourth quarter of 2026, as the year-over-year impact of 2025 product launch ASP mix shift dynamics lap and 2026 new product launches begin contributing revenue - Management expects sequential revenue growth from Q2 to Q3 2026, followed by another sequential step-up in revenue for Q4 2026 in line with historical seasonality - Management expects to deliver continued adjusted EBITDA improvement in 2027 and has indicated positive adjusted EBITDA is achievable for full year 2027
Segment performance
Treace Medical Concepts does not break out financial performance for separate product segments in this call. Total company revenue for Q2 2026 was $45.4 million, a 4% year-over-year decrease. Total operating expenses were $50.6 million, an 8% year-over-year decrease. Net loss for the quarter was $15.9 million ($0.24 per share), compared to a net loss of $17.4 million ($0.28 per share) in Q2 2025. Adjusted EBITDA loss was 57% lower than the prior year period at $3.6 million. Cash, cash equivalents, and marketable securities totaled $45.6 million as of June 30, 2026. The company's Focus Direct sales team contributes approximately 80% of total company revenue.
Risks & headwinds
- Forward-looking statements are inherently subject to material risks and uncertainties that could cause actual results to differ materially from management's current expectations, as detailed in the company's SEC filings including its 2025 Form 10-K and Q2 2026 Form 10-Q - General industry risks include potential slowdowns in elective orthopedic procedures stemming from factors such as ACA subsidy expirations; as of Q2 2026, management has not observed a material impact to Treace's patient base, which is majority commercially insured - The company operates in a competitive market with both large established competitors and smaller niche players, and faces the risk of competitive imitation of its innovative product offerings - Product adoption and revenue growth depend on successful surgeon training, sales force execution, and sustained clinical demand for new procedures, which may not meet expectations
Analyst Q&A
Q: The analyst asked for a breakdown of recent quarter-over-quarter changes in case volume and pricing, and how new product launches have impacted these dynamics. /
A: Management noted that penetration of the three 2025-launched bunion systems grew from 35% to 40% of the existing surgeon base quarter-over-quarter, with early contributions from the newly launched SuperBite screw system. These combined drove case volume growth acceleration from the prior mid single digits pace to high single digits in Q2 2026, in line with the company's planned execution.
Q: The analyst asked what the addressable market size is for the company's new midfoot and hindfoot product portfolio. /
A: Management confirmed that the full mid/hindfoot platform (SuperBite, HyperPlate XM, Great Release XM, and Cartoblaster) expands the company's U.S. total addressable market by approximately $300 million, with adoption varying by surgeon preference for different new bunion system offerings, and strong broad-based adoption of the Speed MTP system.
Q: The analyst asked what competitive response the company has seen to its new product innovations, and how quickly competitors could replicate these offerings. /
A: Management stated there has been no notable shift in the competitive landscape since the prior quarter. The company's competitive advantages include best-in-class surgeon medical education, a highly specialized direct sales force, and a sustained pace of pipeline innovation that supports ongoing market share gains, which the company will continue to prioritize.
Q: The analyst asked if third quarter 2026 revenue will step up sequentially from Q2, if the Q2 operating expense run rate is sustainable, and if an adjusted EBITDA break-even in 2027 is a realistic expectation. /
A: Management confirmed a sequential Q3 revenue step-up over Q2 is expected, in line with the trajectory toward a seasonally strong Q4. Restructuring and efficiency efforts have driven a lower operating expense run rate that allows for continued investment in R&D and commercial growth while improving profitability; management expects positive adjusted EBITDA for full year 2027 is achievable. The company has also not observed any material impact from broader industry elective procedure slowdown concerns, as most of its patients are commercially insured.